DermaSensor, Inc. has developed a groundbreaking handheld device that utilizes Elastic Scattering Spectroscopy (ESS) to enhance skin cancer detection at the point of care. This innovative technology allows physicians to assess suspicious skin lesions by analyzing how light scatters off cellular and sub-cellular structures. The device captures five spectral recordings from a lesion, which are then processed by an advanced algorithm to provide immediate assessments, categorizing lesions as "Monitor" or "Investigate Further." This rapid analysis empowers primary care physicians with objective, actionable insights, improving their confidence in referral decisions and potentially increasing the early detection of skin cancers such as melanoma, squamous cell carcinoma, and basal cell carcinoma.

In addition to its core functionality, DermaSensor's device is designed to seamlessly integrate into various clinical settings, including private practices, health systems, and walk-in clinics. The AI-powered platform not only enhances patient assessment but also supports healthcare providers in managing their patient populations more effectively. With FDA clearance, the device represents a significant advancement in non-invasive skin cancer detection, offering a user-friendly solution that requires minimal training for healthcare professionals. DermaSensor's commitment to innovation is further underscored by its ongoing clinical studies, which validate the effectiveness of its technology in real-world applications, solidifying its role as a leader in skin health solutions.

United States

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

DermaSensor, Inc.

Company Details